A severe dermatologic adverse effect related with gefitinib: Case report and review of the literature

Journal of Cancer Research and Therapeutics

Volumn 9, Issue SUPPL. 2, 2013, Pages

  Li, Yuan Qing ^a   Sun, Hong ^a   Xue, Dong ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Dermatologic adverse effect; gefitinib; the epidermal growth factor inhibitor

Indexed keywords

CA 125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ETHACRIDINE LACTATE; GEFITINIB; GEMCITABINE; LORATADINE;

ACNE; ADULT; BONE METASTASIS; BRAIN METASTASIS; BRONCHOSCOPE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CASE REPORT; CHEST PRURITUS; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DRUG ERUPTION; DRUG WITHDRAWAL; ERYTHEMA; FACE PRURITUS; GENE MUTATION; HIP PAIN; HUMAN; LICHENOID ERUPTION; LIMB PAIN; LUNG ADENOCARCINOMA; LUNG BIOPSY; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL PRURITUS; PHYSICAL PERFORMANCE; PRURITUS; REVIEW; SKIN EXFOLIATION; SKIN REDNESS; SKIN SWELLING; SYSTEMIC THERAPY; TABLET; THORAX RADIOGRAPHY; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; EDEMA; ERYTHEMA; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; QUINAZOLINES;

EID: 84885624761     PISSN: 09731482     EISSN: 19984138     Source Type: Journal    
DOI: 10.4103/0973-1482.119123     Document Type: Review

References (34)

1. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 2002;7 Suppl 4:2-8.
2. Su Z. Epidermal growth factor receptor mutation-guided treatment for lung cancers: Where are we now? Thorac Cancer 2011;2:1-6.
3. Ricciardi S, Tomao S, de Marinis F. Toxicity of targeted therapy in non-small-cell lung cancer management. Clin Lung Cancer 2009;10:28-35.
4. Yang C, Fukuoka M, Mok TS, et al. Final Overall Survival (OS) Results from a Phase III, Randomised, Open-Label, First-Line Study of Gefitinib (G) v Carboplatin/Paclitaxel (C/P) in Clinically Selected Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) in Asia (IPASS). Abstract LBA2. ESMO; 2010.
5. Huang Z, Wang Z, Bai H, Wu M, An T, Zhao J, et al. The detection of EGFR mutation status in plasma is reproducible and can dynamically predict the efficacy of EGFR-TKI. Thorac Cancer 2012;3:334-40.
6. Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised phase III trial. Lancet 2008;372:1809-18.
7. Azzoli CG, Baker S Jr, Temin S, Pao W, Aliff T, Brahmer J, et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009;27:6251-66.
8. Joshi SS, Ortiz S, Witherspoon JN, Rademaker A, West DP, Anderson R, et al. Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life. Cancer 2010;116:3916-23.
9. Agha R, Kinahan K, Bennett CL, Lacouture ME. Dermatologic challenges in cancer patients and survivors. Oncology (Williston Park) 2007;21:1462-72.
10. Wagner LI, Lacouture ME. Dermatologic toxicities associated with EGFR inhibitors: The clinical psychologist's perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae. Oncology (Williston Park) 2007;21:34-6.
11. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004;22:77-85.
12. Chen AP, Setser A, Anadkat MJ, Cotliar J, Olsen EA, Garden BC, et al. Grading dermatologic adverse events of cancer treatments: The common terminology criteria for adverse events version 4.0. J Am Acad Dermatol 2012;67:1025-39.
13. Balagula Y, Rosen ST, Lacouture ME. The emergence of supportive oncodermatology: The study of dermatologic adverse events to cancer therapies. J Am Acad Dermatol 2011;65:624-35.
14. Perez-Soler R, Delord JP, Halpern A, Kelly K, Krueger J, Sureda BM, et al. HER1/EGFR inhibitor-associated rash: Future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 2005;10:345-56.
15. Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: Is there a silver lining? J Clin Oncol 2005;23:5235-46.
16. Saltz L, Kies M, Abbruzzese JL, Needle M. The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Proc Am Soc Clin Oncol 2003;22:204.
17. Racca P, Fanchini L, Caliendo V, Ritorto G, Evangelista W, Volpatto R, et al. Efficacy and skin toxicity management with cetuximab in metastatic colorectal cancer: Outcomes from an oncologic/dermatologic cooperation. Clin Colorectal Cancer 2008;7:48-54.
18. Herbst RS, Prager D, Hermann R. TRIBUTE: A phase III trial of erlotinib HCL (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2004;22:617.
19. Gatzemeier U, Pluzanska A, Szczesna A. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2004;22:617.
20. Perez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, et al. Determinants of tumor response and survival with erlotinib in patients with non - Small-cell lung cancer. J Clin Oncol 2004;22:3238-47.
21. Rowinsky EK, Schwartz GH, Gollob JA, Thompson JA, Vogelzang NJ, Figlin R, et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 2004;22:3003-15.
22. Peeters M, Siena S, Van Cutsem E, Sobrero A, Hendlisz A, Cascinu S, et al. Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. Cancer 2009;115:1544-54.
23. Tejpar S, Peeters M, Humbler Y. The EVEREST study: Relationship between efficacy and K-ras mutation status in patients with irinotecan-refractory mCRC treated with irinotecan and standard or escalating doses of cetuximab. Ann Oncol 2008;19 Suppl Vi: 14.
24. Karthaus M, Speiss G, Hofheinz R. Management of epidermal-growth factor receptor inhibitor-related skin toxicity: A first-line, phase II study (20060314) of panitumumab with FOLFIRI in the treatment of metastatic colorectal cancer. Ann Oncol 2009;20 Suppl 7:Vii12.
25. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 2003;290:2149-58.
26. Cohen EE, Rosen F, Stadler WM, Recant W, Stenson K, Huo D, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003;21:1980-7.
27. Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 2004;22:133-42.
28. Burtness B, Anadkat M, Basti S, Hughes M, Lacouture ME, McClure JS, et al. NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer. J Natl Compr Canc Netw 2009;7 Suppl 1:S5-21.
29. Potthoff K, Hofheinz R, Hassel JC, Volkenandt M, Lordick F, Hartmann JT, et al. Interdisciplinary management of EGFR-inhibitor-induced skin reactions: A German expert opinion. Ann Oncol 2011;22:524-35.
30. Scope A, Agero AL, Dusza SW, Myskowski PL, Lieb JA, Saltz L, et al. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol 2007;25:5390-6.
31. Herbst RS, LoRusso PM, Purdom M, Ward D. Dermatologic side effects associated with gefitinib therapy: Clinical experience and management. Clin Lung Cancer 2003;4:366-9.
32. Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N, et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 2010;28:1351-7.
33. Lacouture ME. The growing importance of skin toxicity in EGFR inhibitor therapy. Oncology (Williston Park) 2009;23:194, 196.
34. Lacouture ME, Mitchell E, Shearer H, et al. Impact of pre-emptive skin toxicity (ST) treatment on panitumumab (pmab)-related skin toxicities and quality of life (QOL) in patients (pts) with metastatic colorectal cancer (mCRC). Results from STEPP. Gastrointestinal Cancer Symposium, 15-17 January, (Abstr 291), San Francisco, CA, 2009.